Compare JD & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JD | NTRA |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2B | 45.3B |
| IPO Year | 2014 | 2015 |
| Metric | JD | NTRA |
|---|---|---|
| Price | $29.39 | $331.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $39.27 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 9.0M | 1.3M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $8.17 | $18.08 |
| Revenue Next Year | $6.01 | $19.65 |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.51 | $157.43 |
| 52 Week High | $36.86 | $333.56 |
| Indicator | JD | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 71.73 |
| Support Level | $28.38 | $187.64 |
| Resistance Level | $30.44 | N/A |
| Average True Range (ATR) | 0.68 | 10.88 |
| MACD | -0.44 | 2.40 |
| Stochastic Oscillator | 21.44 | 96.11 |
JD.com is the third-largest Chinese e-commerce platform by gross merchandise volume in 2025. It offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace, and omnichannel businesses.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.